Clinical trials: Epithelial Mesothelioma
Malignant Pleural Mesothelioma
Everolimus (RAD001) for the Treatment of Malignant Pleural Mesothelioma With Merlin/NF2 Loss as a Biomarker to Predict Sensitivity
For patients with malignant pleural mesothelioma that has grown despite treatment with standard chemotherapy, no treatment has yet proven beneficial.
- Trial name
- NCT01024946
- Testing
- everolimus
- Where
- 3 sites in United States
- Volunteers
- 11 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Malignant Mesothelioma, Metastatic Malignant Solid Tumor
Study of ISM6331 in Participants With Advanced/Metastatic Mesothelioma or Other Advanced Solid Tumors
This is a Phase 1/2, open-label, multicenter, FIH study to evaluate the safety, tolerability, recommended Phase 2 dose (RP2D), PK/PD, and preliminary anti-tumor activity of ISM6331 in participants with advanced or metastatic…
- Conditions
- Malignant Mesothelioma, Metastatic Malignant Solid Tumor, Advanced Solid Tumor
- Trial name
- NCT06566079
- Testing
- ISM6331
- Where
- 10 sites in United States, China
- Volunteers
- 160 people
- Sponsor
- InSilico Medicine Hong Kong Limited
Pleural Mesothelioma, Metastatic Pleural Effusions
Gene Therapy for Pleural Malignancies
This Phase I study will evaluate the safety of two doses of BG00001 at different doses and intervals. Eligible subjects will have: malignant pleural mesothelioma, or pleural effusions who have progressed through at least one…
- Trial name
- NCT00299962
- Testing
- Adenoviral-mediated Interferon-beta, SCH 721015
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of Pennsylvania
Thoracic Cancers, Malignant Pleural Mesotheliomas NOS
Evaluation of Cell Changes in Blood and Tissue in Cancers of the Lung, Esophagus and Lung Lining
Background: Chromatin is is the structural building block of a chromosome. It is found inside the nucleus of the cell and consists of a complex of DNA and protein.
- Conditions
- Thoracic Cancers, Malignant Pleural Mesotheliomas NOS, Lung Cancer NOS, Esophageal Cancers NOS
- Trial name
- NCT00242723
- Where
- United States
- Volunteers
- 1,559 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Esophageal Cancers, Primary Small Cell Lung Cancers
Phase I Study of Gene Induction Mediated by Sequential Decitabine/Depsipeptide Infusion With or Without Concurrent Celecoxib in Subjects With Pulmonary and Pleural Malignancies
Background: Previously we have demonstrated induction of tumor antigen and tumor suppressor gene expression in lung cancer cells following exposure to the DNA demethylating agent, Decitabine (DAC).
- Conditions
- Advanced Esophageal Cancers, Primary Small Cell Lung Cancers, Non-Small-Cell Lung Carcinoma, Pleural Mesotheliomas
- Trial name
- NCT00037817
- Testing
- Decitabine, Depsipeptide, Celecoxib
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- National Cancer Institute (NCI)
Pleural Mesothelioma, Non-small Cell Lung Cancer
A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma (Pegathor Lung 202)
The Primary Objective was: -To determine the antitumor activity of SAR444245 in combination with other anticancer therapies. The Secondary Objectives were: To confirm the dose and to assess the safety profile of SAR444245 when…
- Trial name
- NCT04914897
- Testing
- THOR-707, Pembrolizumab
- Where
- 35 sites in United States, Argentina and 9 more
- Volunteers
- 106 people
- Sponsor
- Sanofi
Pleural Mesothelioma, Pleural Diseases
The Diagnostic Accuracy and Clinical Value of FAPI PET in Pleural Mesothelioma
Seventy (N=70) patients with suspected pleural mesothelioma (PM) lesions referred to pleural biopsy will be recruited, and undergo an additional FAPI PET/CT at primary staging.
- Conditions
- Pleural Mesothelioma, Pleural Diseases, Cancer, FAPI
- Trial name
- FAPI-PM (NCT06790082)
- Testing
- [68Ga]Ga-FAPI-46 PET/CT
- Where
- Denmark
- Volunteers
- 70 people
- Sponsor
- Aalborg University Hospital
Malignant Pleural Mesothelioma
Study of NGR-hTNF as Single Agent in Patients Affected by Advanced or Metastatic Malignant Pleural Mesothelioma
The main objective of the trial is to document the progression free survival (PFS) in advanced or metastatic malignant pleural mesothelioma patients treated with NGR-hTNF as single agent.
- Trial name
- NGR010 (NCT00484276)
- Testing
- NGR-hTNF
- Where
- 4 sites in Italy
- Volunteers
- 57 people
- Sponsor
- AGC Biologics S.p.A.
Clinical Trial, Phase I, Neuroendocrine Tumors
177Lu-DOTA-TATE and Olaparib in Somatostatin Receptor Positive Tumours
This is a phase I study of 177Lu-DOTA-TATE in combination with the PARP-inhibitor olaparib for treatment of patients with somatostatin receptor positive tumours detected by 68Ga-DOTA-TATE/TOC PET.
- Conditions
- Clinical Trial, Phase I, Neuroendocrine Tumors, Thymoma, Mesothelioma
- Trial name
- LuPARP (NCT04375267)
- Testing
- 177Lu-DOTA-TATE + olaparib
- Where
- Sweden
- Volunteers
- 18 people
- Sponsor
- Vastra Gotaland Region
Renal Cell Cancer, Castrate Resistant Prostate Cancer
TT-4 and TT-10 as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors and Pleural Mesothelioma
The goal of this clinical trial is to evaluate TT-10, TT-4 and TT-10 + TT-4, (Dual Blockade) in participants with advanced selected solid tumors, who have failed or are not eligible for standard of care.
- Conditions
- Renal Cell Cancer, Castrate Resistant Prostate Cancer, Non Small Cell Lung Cancer, Pleural Mesothelioma Malignant
- Trial name
- NCT04969315
- Testing
- TT-10, TT-4
- Where
- 2 sites in United States
- Volunteers
- 35 people
- Sponsor
- Portage Biotech
Neoplasms, Prostatic Neoplasms, Castration-Resistant
HTL0039732 in Participants With Advanced Solid Tumours
The purpose of this trial is to evaluate a new drug, HTL0039732, that will be administered on its own (as a monotherapy) and in combination with atezolizumab or with other approved anti-cancer therapies, in participants with…
- Conditions
- Neoplasms, Prostatic Neoplasms, Castration-Resistant, Stomach Neoplasms, Esophageal Neoplasms
- Trial name
- NCT05944237
- Testing
- HTL0039732 Capsules, HTL0039732 Capsules or HTL0039732 tablets and atezolizumab infusion
- Where
- 6 sites in United Kingdom
- Volunteers
- 150 people
- Sponsor
- Cancer Research UK
Mesothelioma, Solitary Fibrous Tumor of the Pleura
Surgery for Mesothelioma After Radiation Therapy "SMART" for Resectable Malignant Pleural Mesothelioma
The purpose of this study is to determine whether radiation therapy decreases tumor size and tumor spread. The investigators will consent subjects that have been diagnosed with mesothelioma and will undergo radiation therapy…
- Trial name
- NCT02613299
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Mayo Clinic
Mesothelioma, Glioblastoma
Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
Study of NGM707 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
- Conditions
- Mesothelioma, Glioblastoma, Renal Cell Carcinoma, Non Small Cell Lung Cancer
- Trial name
- NCT04913337
- Testing
- NGM707, NGM707 plus pembrolizumab (KEYTRUDA®)
- Where
- 27 sites in United States, South Korea and 1 more
- Volunteers
- 179 people
- Sponsor
- NGM Biopharmaceuticals, Inc
Malignant Pleural Mesothelioma
Using E-Nose Technology to Measure Response to Treatment in People With Malignant Pleural Mesothelioma
The researchers are doing this study to test the ability of a new technology called breathprinting, or electronic nose (E-Nose), to measure how people respond to standard treatment for malignant pleural mesothelioma (MPM).
- Trial name
- NCT06037941
- Testing
- E-Nose testing, Research blood
- Where
- 7 sites in United States
- Volunteers
- 20 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Malignant Mesothelioma
Phase II Study of Valproate and Doxorubicin in Malignant Mesothelioma
The purpose of this study is to determine the response rate to the combination of doxorubicin and valproate acid in patients with MM failing after at least one previous chemotherapy regimen including platinum derivatives .
- Trial name
- NCT00634205
- Testing
- Valproate plus doxorubicin
- Where
- 8 sites in Belgium, France
- Volunteers
- 45 people
- Sponsor
- European Lung Cancer Working Party
Malignant Pleural Mesothelioma
Four Versus Six Cycles of Pemetrexed/Platinum for MPM
The prognosis of mesothelioma is generally poor. The median survival of patients with unresectable malignant mesothelioma ranges approximately between 6-12 months. Survival is poor because there is no curative treatment.
- Trial name
- NCT02497053
- Testing
- pemetrexed/platinum chemotherapy
- Where
- Egypt
- Volunteers
- 70 people
- Sponsor
- Ain Shams University
Lung Neoplasm Malignant, Mesothelioma; Lung
Feasibility Trial of a Personalised Nutrition and Activity Programme for People With Lung Cancer Over 65 Years
People with cancer affecting the lungs tend to be older and frailer compared to people with other cancers. As a result, they may have poorer quality of life and are less able to tolerate treatments for their cancer, such as…
- Trial name
- CanBenefitII (NCT05404022)
- Testing
- Tailored nutrition and physical activity programme
- Where
- 2 sites in United Kingdom
- Volunteers
- 11 people
- Sponsor
- University of Hull
Malignant Pleural Mesothelioma
Standard Chemotherapy With of Without Axitinib in Malignant Mesothelioma
The purpose of this study is to investigate the effects of axitinib, a potent angiogenesis inhibitor, on tissue and clinical outcome in combination with chemotherapy given to patients with mesothelioma
- Trial name
- N08CPA (NCT01211275)
- Testing
- axitinib, chemotherapy
- Where
- Netherlands
- Volunteers
- 32 people
- Sponsor
- The Netherlands Cancer Institute
Advanced Solid Tumors
A Study of Budigalimab (ABBV-181) in Participants With Advanced Solid Tumors
This is an open-label, Phase I, dose-escalation study to determine the recommended Phase 2 dose (RPTD), maximum tolerated dose (MTD), and evaluate the safety and pharmacokinetic (PK) profile of budigalimab.
- Trial name
- NCT03000257
- Testing
- Venetoclax, Rovalpituzumab Tesirine, ABBV-181
- Where
- 26 sites in United States, Australia and 8 more
- Volunteers
- 182 people
- Sponsor
- AbbVie
Malignant Pleural Mesothelioma, Mesothelioma
Transarterial Chemoperfusion: Cisplatin, Methotrexate, Gemcitabine for Unresectable Pleural Mesothelioma
The purpose of this study is to determine whether the transarterial chemoperfusion treatment with cisplatin, methotrexate and gemcitabine is safe and effective in adults with malignant pleural mesothelioma (MPM).
- Trial name
- NCT02611037
- Testing
- Cisplatin, Methotrexate, Gemcitabine
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute